The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC), the largest component of the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a small, statistically non-significant reduction in prostate cancer-specific mortality by systematic PSA-based screening1,2. Here, KLK3 is linked to prostate carcinoma.